Angiogenesis

Microcirculation

Volumn , Issue , 2008, Pages 351-383

  Gerritsen, Mary E ^a  

^a EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866267281     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374530-9.00008-5     Document Type: Chapter

References (368)

1. G.E. Davis and C.W. Camarillo (1996) An alpha 2 beta 1 integrin-dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix. Exp Cell Res 224 39-51.
2. R. Salazar, S.E. Bell and G.E. Davis (1999) Coordinate induction of the actin cytoskeletal regulatory proteins gelsolin, vasodilator-stimulated phosphoprotein, and profilin during capillary morphogenesis in vitro. Exp Cell Res 249 22-32.
3. K.J. Bayless, R. Salazar and G.E. Davis (2000) RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol 156 1673-1683.
4. K.J. Bayless and G.E. Davis (2002) The Cdc42 and Rac1 GTPases are required for capillary lumen formation in three-dimensional extracellular matrices. J Cell Sci 115 1123-1136.
5. M. Kamei, W.B. Saunders, K.J. Bayless, L. Dye, G.E. Davis and B.M. Weinstein (2006) Endothelial tubes assemble from intracellular vacuoles in vivo. Nature 442 453-456.
6. J. Caduff, L. Fischer and P. Burri (1986) Scanning electron microscopic study of the developing microvasculature in the postnatal rat lung. Anat Rec 216 154-164.
7. C. Suri, P.F. Jones, S. Patan, S. Bartunkova, P.C. Maisonpierre, S. Davis, T.N. Sato and G.D. Yancopoulos (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87 1171-1180.
8. S. Patan (1998) TIE1 and TIE2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth. Microvasc Res 56 1-21.
9. G. Thurston, C. Suri, K. Smith, J. McClain, T. Sato, G. Yancopoulos and D. McDonald (1999) Leakage resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286 2511-2514.
10. J.R. Gamble, J. Drew, L. Trezise, A. Underwood, M. Parsons, L. Kasminkas, J. Rudge, G. Yancopoulos and M.A. Vadas (2000) Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 87 603-607.
11. G. Thurston, J.S. Rudge, E. Ioffe, H. Zhou, L. Ross, S.D. Croll, N. Glazer, J. Holash, D.M. McDonald and G.D. Yancopoulos (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6 460-463.
12. G. Thurston (2002) Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage. J Anat 200 575-580.
13. C.K. Jiang, H.S. Epstein, M. Tomic, I.M. Freedberg and M. Blumenberg (1990) Epithelial-specific keratin gene expression: identification of a 300 base-pair controlling segment. Nucleic Acids Res 18 247-253.
14. P.C. Maisonpierre, C. Suri, P.F. Jones, S. Bartunkova, S.J. Wiegand, C. Radziejewski, D. Compton, J. McClain, T.H. Aldrich, N. Papadopoulos, T.J. Daly, S. Davis, T.N. Sato and G.D. Yancopoulos (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis [see comments]. Science 277 55-60.
15. S. Satchell, S. Harper and P. Mathieson (2001) Angiopoietin-1 is normally expressed by periendothelial cells. Thromb Haemost 86 1597-1598.
16. S.J. Mandriota and M.S. Pepper (1998) Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 83 852-859.
17. D.M. Ornitz, J. Xu, J.S. Colvin, D.G. McEwen, C.A. MacArthur, F. Coulier, G. Gao and M. Goldfarb (1996) Receptor specificity of the fibroblast growth factor family. J Biol Chem 271 15292-15297.
18. W. Burgess and T. Maciag (1989) The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 58 575-606.
19. A. Bikfalvi, S. Klein, G. Pintucci and D. Rifkin (1997) Biological roles of fibroblast growth factor-2. Endocr Rev 18 26-45.
20. T. Imamura, K. Engleka, X. Zhan, Y. Tokita, R. Forough, D. Roeder, A. Jackson, J. Maier, T. Hla and T. Maciag (1990) Recovery of mitogenic activity of a growth factor mutant with a nuclear translocation sequence. Science 249 1567-1570.
21. B. Bugler, F. Amalric and H. Prats (1991) Alternative initiation of translation determines cytoplasmic or nuclear localization of basic fibroblast growth factor. Mol Cell Biol 11 573-577.
22. R. Dono, G. Texido, R. Dussel, H. Ehmke and R. Zeller (1998) Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. Embo J 17 4213-4225.
23. S. Ortega, M. Ittmann, S. Tsang, M. Ehrlich and C. Basilico (1998) Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci USA 95 5672-5677.
24. M. Zhou, R. Sutliff, R. Paul, J. Lorenz, J. Hoying, C. Haudenschild, M. Yin, J. Coffin, L. Kong, E. Kranias, W. Luo, G. Boivin, J. Duffy, S. Pawlowski and T. Doetschman (1998) Fibroblast growth factor 2 control of vascular tone. Nat Med 4 201-207.
25. D.L. Miller, S. Ortega, O. Bashayan, R. Basch and C. Basilico (2000) Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice. Mol Cell Biol 20 2260-2268.
26. M. Simons and A. Horowitz (2001) Syndecan-4 mediated signaling. Cell Signal 13 855-862.
27. E. Tkachenko, E. Lutgens, R.-V. Stan and M. Simons (2004) Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42 dependent macropinocytotic pathway. J Cell Sci 117 3189-3199.
28. L. Donate, E. Gherardi, N. Srinivasan, R. Sowdhamini, S. Aparicio and T. Blundell (1994) Molecular evolution and domain structure of plasminogen-related growth factors (HGF-SF) and HGF1/MSP. Protein Sci 3 2378-2394.
29. P. Boros and M. Miller (1995) Hepatocyte growth factor: a multifunctional cytokine. Lancet 345 293-295.
30. K. Matsumoto and T. Nakamura (1996) Emerging multipotent aspects of hepatocyte growth factor. J Biochem 119 591-600.
31. D.P. Bottaro, J.S. Rubin, D. Faletto, A. Chan, T. Kmiecik, G. Van de Woude and S.A. Aaronson (1991) Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251 802-804.
32. P. Ma, G. Maulik, J. Christensen and R. Salgia (2003) c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 22 309-325.
33. F. Bladt, D. Riethmacher, S. Isenmann, A. Aguzzi and C. Birchmeier (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376 768-771.
34. C. Schmidt, F. Bladt, S. Goedecke, V. Brinkmann, W. Zschiesche, M. Sharpe, E. Gherardi and C. Birchmeier (1995) Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373 699-702.
35. Y. Uehara, O. Minowa, C. Mori, K. Shiota, J. Kuno, T. Noda and N. Kitamura (1995) Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373 702-705.
36. A. Morimoto, K. Okamura, R. Hamanaka, Y. Sato, N. Shima, K. Higashio and M. Kuwano (1991) Hepatocyte growth factor modulates migration and proliferation of human microvascular endothelial cells in culture. Biochem Biophys Res Commun 179 1042-1049.
37. F. Bussolino, M.F. Di Renzo, M. Ziche, E. Bocchietto, M. Olivero, L. Naldini, G. Gaudino, L. Tamagnone, A. Coffer and P.M. Comoglio (1992) Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119 629-641.
38. M. Jeffers, S. Rong and G.F. Woude (1996) Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J Mol Med 74 505-513.
39. E.M. Rosen, K. Lamszus, J. Laterra, P.J. Polverini, J.S. Rubin and I.D. Goldberg (1997) HGF/SF in angiogenesis. Ciba Found Symp 212 215-226. discussion 227–219
40. R. Kumar, J. Yoneda, C.D. Bucana and I.J. Fidler (1998) Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 12 749-757.
41. R. Montesano, J.V. Soriano, K.M. Malinda, M.L. Ponce, A. Bafico, H.K. Kleinman, D.P. Bottaro and S.A. Aaronson (1998) Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis. Cell Growth Differ 9 355-365.
42. E. Van Belle, B. Witzenbichler, D. Chen, M. Silver, L. Chang, R. Schwall and J.M. Isner (1998) Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 97 381-390.
43. X. Xin, S. Yang, G. Ingle, C. Zlot, L. Rangell, J. Kowalski, R. Schwall, N. Ferrara and M.E. Gerritsen (2001) Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 158 1111-1120.
44. M.E. Gerritsen, R. Soriano, S. Yang, C. Zlot, G. Ingle, K. Toy and P.M. Williams (2003) Branching out: a molecular fingerprint of endothelial differentiation into tube-like structures generated by Affymetrix oligonucleotide arrays. Microcirculation 10 63-81.
45. C. Zlot, G. Ingle, J. Hongo, S. Yang, Z. Sheng, R. Schwall, N. Paoni, F. Wang, F.V. Peale Jr. and M.E. Gerritsen (2003) Stanniocalcin 1 is an autocrine modulator of endothelial angiogenic responses to hepatocyte growth factor. J Biol Chem 278 47654-47659.
46. R. Morishita, S. Nakamura, S. Hayashi, Y. Taniyama, A. Moriguchi, T. Nagano, M. Taiji, H. Noguchi, S. Takeshita, K. Matsumoto, T. Nakamura, J. Higaki and T. Ogihara (1999) Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 33 1379-1384.
47. H. Ueda, Y. Sawa, K. Matsumoto, S. Kitagawa-Sakakida, Y. Kawahira, T. Nakamura, Y. Kaneda and H. Matsuda (1999) Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ann Thorac Surg 67 1726-1731.
48. M. Aoki, R. Morishita, Y. Taniyama, I. Kida, A. Moriguchi, K. Matsumoto, T. Nakamura, Y. Kaneda, J. Higaki and T. Ogihara (2000) Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther 7 417-427.
49. Y. Taniyama, R. Morishita, M. Aoki, H. Nakagami, K. Yamamoto, K. Yamazaki, K. Matsumoto, T. Nakamura, Y. Kaneda and T. Ogihara (2001) Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 8 181-189.
50. Y. Taniyama, R. Morishita, K. Hiraoka, M. Aoki, H. Nakagami, K. Yamasaki, K. Matsumoto, T. Nakamura, Y. Kaneda and T. Ogihara (2001) Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 104 2344-2350.
51. I. Ahmet, Y. Sawa, T. Yamaguchi and H. Matsuda (2003) Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart. Ann Thorac Surg 75 1283-1287.
52. S. Sengupta, E. Gherardi, L.A. Sellers, J.M. Wood, R. Sasisekharan and T.P. Fan (2003) Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 23 69-75.
53. R. Morishita, M. Aoki, N. Hashiya, K. Yamasaki, H. Kurinami, S. Shimizu, H. Makino, Y. Takesya, J. Azuma and T. Ogihara (2004) Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther 4 199-206.
54. K. Ono, A. Matsumori, T. Shioi, Y. Furukawa and S. Sasayama (1997) Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 95 2552-2558.
55. T. Sato, H. Fujieda, S. Murao, H. Sato, T. Takeuchi and Y. Ohtsuki (1999) Sequential changes of hepatocyte growth factor in the serum and enhanced c-Met expression in the myocardium in acute myocardial infarction. Jpn Circ J 63 906-908.
56. T. Nakamura, S. Mizuno, K. Matsumoto, Y. Sawa and H. Matsuda (2000) Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 106 1511-1519.
57. S. Yasuda, Y. Goto, T. Baba, T. Satoh, H. Sumida, S. Miyazaki and H. Nonogi (2000) Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J Am Coll Cardiol 36 115-121.
58. T. Sato, Y. Tani, S. Murao, H. Fujieda, H. Sato, M. Matsumoto, T. Takeuchi and Y. Ohtsuki (2001) Focal enhancement of expression of c-Met/hepatocyte growth factor receptor in the myocardium in human myocardial infarction. Cardiovasc Pathol 10 235-240.
59. J.K. Min, Y.M. Lee, J. Hun Kim, Y.M. Kim, S. Wan Kim, S.Y. Lee, Y.S. Gho, G.T. Oh and Y.G. Kwon (2005) Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-κB pathway. Circ Res
60. M.E. Gerritsen, J.E. Tomlinson, C. Zlot, M. Ziman and S. Hwang (2003) Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 140 595-610.
61. P.A. D'Amore and S.R. Smith (1993) Growth factor effects on cells of the vascular wall: a survey. Growth Factors 8 61-75.
62. E.J. Battegay, J. Rupp, L. Iruela-Arispe, E.H. Sage and M. Pech (1994) PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol 125 917-928.
63. P. Leveen, M. Pekny, S. Gebre-Medhin, B. Swolin, E. Larsson and C. Betsholtz (1994) Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8 1875-1887.
64. P. Lindahl, B.R. Johansson, P. Leveen and C. Betsholtz (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277 242-245.
65. M. Hellstrom, H. Gerhardt, M. Kalen, X. Li, U. Eriksson, H. Wolburg and C. Betsholtz (2001) Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 153 543-553.
66. J. Massague (1998) TGF-beta signal transduction. Annu Rev Biochem 67 753-791.
67. Y. Shi and J. Massague (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 685-700.
68. P. O'Connell, A. McKenzie, N. Fisicaro, S. Rockman, M. Pearse and A. d'Apice (1992) Endoglin: a 180-kD endothelial cell and macrophage restricted differentiation molecule. Clin Exp Immunol 90 154-159.
69. S. Wong, L. Hamel, S. Chevalier and A. P (2000) Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur J Biochem 267 5550-5560.
70. L. Pierelli, G. Bonanno, S. Rutella, M. Marone, G. Scambia and G. Leone (2001) CD105 (endoglin) expression on hematopoietic stem/progenitor cells. Leuk Lymphoma 42 1195-1206.
71. E.Y. Yang and H.L. Moses (1990) Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111 731-741.
72. G.D. Phillips, R.A. Whitehead and D.R. Knighton (1992) Inhibition by methylprednisolone acetate suggests an indirect mechanism for TGF-B induced angiogenesis. Growth Factors 6 77-84.
73. A. Kulkarni, C. Huh, D. Becker, A. Geiser, M. Lyght, K. Flanders, A. Roberts, M. Sporn, J. Ward and S. Karlsson (1993) Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90 770-774.
74. M. Dickson, J. Martin, F. Cousins, A. Kulkarni, S. Karlsson and R. Akhurst (1995) Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice. Development 121 1845-1854.
75. J. Larsson, M. Goumans, L. Sjostrand, M. van Rooijen, D. Ward, P. Leveen, X. Xu, P. ten Dijke, C. Mummery and S. Karlsson (2001) Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. Embo J 20 1663-1673.
76. A. Bourdeau, D.J. Dumont and M. Letarte (1999) A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104 1343-1351.
77. M.J. Goumans and C. Mummery (2000) Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice. Int J Dev Biol 44 253-265.
78. S.E. Duff, C. Li, J.M. Garland and S. Kumar (2003) CD105 is important for angiogenesis: evidence and potential applications. Faseb J 17 984-992.
79. J.A. Tuxhorn, S.J. McAlhany, F. Yang, T.D. Dang and D.R. Rowley (2002) Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 62 6021-6025.
80. F. Zhang, J. Lee, S. Lu, C.A. Pettaway and Z. Dong (2005) Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res 11 4512-4520.
81. T. Martone, P. Rosso, R. Albera, G. Migliaretti, F. Fraire, L. Pignataro, G. Pruneri, G. Bellone and G. Cortesina (2005) Prognostic relevance of CD105+microvessel density in HNSCC patient outcome. Oral Oncol 41 147-155.
82. H.C. Chuang, C.Y. Su, H.Y. Huang, C.Y. Chien, C.M. Chen and C.C. Huang (2006) High expression of CD105 as a prognostic predictor of early tongue cancer. Laryngoscope 116 1175-1179.
83. P.A. Kyzas, N.J. Agnantis and D. Stefanou (2006) Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Arch 448 768-775.
84. C. Taskiran, O. Erdem, A. Onan, O. Arisoy, A. Acar, C. Vural, M. Erdem, O. Ataoglu and H. Guner (2006) The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer 16 1789-1793.
85. M. Autiero, A. Luttun, M. Tjwa and P. Carmeliet (2003) Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 1 1356-1370.
86. J. Kahn, F. Mehraban, G. Ingle, X. Xin, J. Bryant, G. Vehar, J. Schoenfeld, C. Grimaldi, F. Peale, A. Drakharapu, D. Lewin and M. Gerritsen (2000) Gene expression profiling in an in vitro model of angiogenesis. Am J Pathol 156 1887-1900.
87. S.E. Bell, A. Mavila, R. Salazar, K.J. Bayless, S. Kanagala, S.A. Maxwell and G.E. Davis (2001) Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J Cell Sci 114 2755-2773.
88. W. Yang, H. Ahn, M. Hinrichs, R.J. Torry and D.S. Torry (2003) Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells. J Reprod Immunol 60 53-60.
89. S. Iyer, D.D. Leonidas, G.J. Swaminathan, D. Maglione, M. Battisti, M. Tucci, M.G. Persico and K.R. Acharya (2001) The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 A resolution. J Biol Chem 276 12153-12161.
90. P. Carmeliet, L. Moons, A. Luttun, V. Vincenti, V. Compernolle, M. De Mol, Y. Wu, F. Bono, L. Devy, H. Beck, D. Scholz, T. Acker, T. DiPalma, M. Dewerchin, A. Noel, I. Stalmans, A. Barra, S. Blacher, T. Vandendriessche, A. Ponten, U. Eriksson, K.H. Plate, J.M. Foidart, W. Schaper, D.S. Charnock-Jones, D.J. Hicklin, J.M. Herbert, D. Collen and M.G. Persico (2001) Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7 575-583.
91. J. Lagercrantz, F. Farnebo, C. Larsson, T. Tvrdik, G. Weber and F. Piehl (1998) A comparative study of the expression patterns for vegf, vegf-b/vrf and vegf-c in the developing and adult mouse. Biochim Biophys Acta 1398 157-163.
92. B. Olofsson, E. Korpelainen, M.S. Pepper, S.J. Mandriota, K. Aase, V. Kumar, Y. Gunji, M.M. Jeltsch, M. Shibuya, K. Alitalo and U. Eriksson (1998) Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 95 11709-11714.
93. K. Aase, G. von Euler, X. Li, A. Ponten, P. Thoren, R. Cao, Y. Cao, B. Olofsson, S. Gebre-Medhin, M. Pekny, K. Alitalo, C. Betsholtz and U. Eriksson (2001) Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation 104 358-364.
94. B. Olofsson, K. Pajusola, A. Kaipainen, G. von Euler, V. Joukov, O. Saksela, A. Orpana, R.F. Pettersson, K. Alitalo and U. Eriksson (1996) Vascular endothelial growth factor B a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93 2576-2581.
95. J.S. Silvestre, R. Tamarat, T.G. Ebrahimian, A. Le-Roux, M. Clergue, F. Emmanuel, M. Duriez, B. Schwartz, D. Branellec and B.I. Levy (2003) Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res 93 114-123.
96. J. Lee, A. Gray, J. Yuan, S.M. Luoh, H. Avraham and W.I. Wood (1996) Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 93 1988-1992.
97. M.G. Achen, M. Jeltsch, E. Kukk, T. Makinen, A. Vitali, A.F. Wilks, K. Alitalo and S.A. Stacker (1998) Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95 548-553.
98. A. Kaipainen, J. Korhonen, T. Mustonen, V.W. van Hinsbergh, G.H. Fang, D. Dumont, M. Breitman and K. Alitalo (1995) Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 92 3566-3570.
99. E. Kukk, A. Lymboussaki, S. Taira, A. Kaipainen, M. Jeltsch, V. Joukov and K. Alitalo (1996) VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122 3829-3837.
100. M. Detmar, L.F. Brown, M.P. Schon, B.M. Elicker, P. Velasco, L. Richard, D. Fukumura, W. Monsky, K.P. Claffey and R.K. Jain (1998) Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111 1-6.
101. T. Veikkola, L. Jussila, T. Makinen, T. Karpanen, M. Jeltsch, T.V. Petrova, H. Kubo, G. Thurston, D.M. McDonald, M.G. Achen, S.A. Stacker and K. Alitalo (2001) Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. Embo J 20 1223-1231.
102. D.J. Dumont, L. Jussila, J. Taipale, A. Lymboussaki, T. Mustonen, K. Pajusola, M. Breitman and K. Alitalo (1998) Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282 946-949.
103. V. Joukov, A. Kaipainen, M. Jeltsch, K. Pajusola, B. Olofsson, V. Kumar, U. Eriksson and K. Alitalo (1997) Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol 173 211-215.
104. V. Joukov, T. Sorsa, V. Kumar, M. Jeltsch, L. Claesson-Welsh, Y. Cao, O. Saksela, N. Kalkkinen and K. Alitalo (1997) Proteolytic processing regulates receptor specificity and activity of VEGF-C. Embo J 16 3898-3911.
105. N. Ferrara, K. Carver-Moore, H. Chen, M. Dowd, L. Lu, K.S. O'Shea, L. Powell-Braxton, K.J. Hillan and M.W. Moore (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 439-442.
106. N. Ferrara, H.P. Gerber and J. LeCouter (2003) The biology of VEGF and its receptors. Nat Med 9 669-676.
107. T. Cohen, H. Gitay-Goren, R. Sharon, M. Shibuya, R. Halaban, B.Z. Levi and G. Neufeld (1995) VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 270 11322-11326.
108. G. Neufeld, T. Cohen, H. Gitay-Goren, Z. Poltorak, S. Tessler, R. Sharon, S. Gengrinovitch and B.Z. Levi (1996) Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev 15 153-158.
109. Z. Gluzman-Poltorak, T. Cohen, Y. Herzog and G. Neufeld (2000) Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J Biol Chem 275 18040-18045.
110. Z. Poltorak, T. Cohen and G. Neufeld (2000) The VEGF splice variants: properties, receptors, and usage for the treatment of ischemic diseases. Herz 25 126-129.
111. J.S. Krussel, B. Behr, A.A. Milki, J. Hirchenhain, Y. Wen, P. Bielfeld and M. Lake Polan (2001) Vascular endothelial growth factor (VEGF) mRNA splice variants are differentially expressed in human blastocysts. Mol Hum Reprod 7 57-63.
112. C.J. Robinson and S.E. Stringer (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114 853-865.
113. W. Petersen, T. Pufe, F. Unterhauser, T. Zantop, R. Mentlein and A. Weiler (2003) The splice variants 120 and 164 of the angiogenic peptide vascular endothelial cell growth factor (VEGF) are expressed during Achilles tendon healing. Arch Orthop Trauma Surg 123 475-480.
114. S. Yang, X. Xin, C. Zlot, G. Ingle, G. Fuh, B. Li, B. Moffat, A.M. de Vos and M.E. Gerritsen (2001) Vascular endothelial cell growth factor-driven endothelial tube formation is mediated by vascular endothelial cell growth factor receptor-2, a kinase insert domain-containing receptor. Arterioscler Thromb Vasc Biol 21 1934-1940.
115. S. Yang, K. Toy, G. Ingle, C. Zlot, P.M. Williams, G. Fuh, B. Li, A. de Vos and M.E. Gerritsen (2002) Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol 22 1797-1803.
116. S. Soker, S. Takashima, H.Q. Miao, G. Neufeld and M. Klagsbrun (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92 735-745.
117. M. Klagsbrun, S. Takashima and R. Mamluk (2002) The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 515 33-48.
118. A.M. Dvorak, S. Kohn, E.S. Morgan, P. Fox, J.A. Nagy and H.F. Dvorak (1996) The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukoc Biol 59 100-115.
119. A.M. Dvorak and D. Feng (2001) The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J Histochem Cytochem 49 419-432.
120. J.W. Fett, D.J. Strydom, R.R. Lobb, E.M. Alderman, J.L. Bethune, J.F. Riordan and B.L. Vallee (1985) Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 24 5480-5486.
121. K. Kurachi, E.W. Davie, D.J. Strydom, J.F. Riordan and B.L. Vallee (1985) Sequence of the cDNA and gene for angiogenin, a human angiogenesis factor. Biochemistry 24 5494-5499.
122. D.J. Strydom, J.W. Fett, R.R. Lobb, E.M. Alderman, J.L. Bethune, J.F. Riordan and B.L. Vallee (1985) Amino acid sequence of human tumor derived angiogenin. Biochemistry 24 5486-5494.
123. A. Wiedlocha (1999) Following angiogenin during angiogenesis: a journey from the cell surface to the nucleolus. Arch Immunol Ther Exp (Warsz) 47 299-305.
124. R. Shapiro, J.F. Riordan and B.L. Vallee (1986) Characteristic ribonucleolytic activity of human angiogenin. Biochemistry 25 3527-3532.
125. R. Shapiro and B.L. Vallee (1987) Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin. Proc Natl Acad Sci USA 84 2238-2241.
126. S.A. Adams and V. Subramanian (1999) The angiogenins: an emerging family of ribonuclease related proteins with diverse cellular functions. Angiogenesis 3 189-199.
127. R. Shapiro, D.J. Strydom, K.A. Olson and B.L. Vallee (1987) Isolation of angiogenin from normal human plasma. Biochemistry 26 5141-5146.
128. J. Badet (1999) Angiogenin, a potent mediator of angiogenesis. Biological, biochemical and structural properties. Pathol Biol (Paris) 47 345-351.
129. J. Zhang and Y.P. Zhang (2003) Pseudogenization of the tumor-growth promoter angiogenin in a leaf-eating monkey. Gene 308 95-101.
130. B. Moore, M. Keane, C. Addison, D. Arenberg and R. Streiter (1998) CXC chemokine modulation of angiogenesis: the importance of balance between angiogenic and angiostatic members of the family. J Invest Med 46 113-120.
131. M.M. Rosenkilde and T.W. Schwartz (2004) The chemokine system – a major regulator of angiogenesis in health and disease. APMIS 112 481-495.
132. R.M. Devalaraja, L.B. Nanney, J. Du, Q. Qian, Y. Yu, M.N. Devalaraja and A. Richmond (2000) Delayed wound healing in CXCR2 knockout mice. J Invest Dermatol 115 234-244.
133. M.P. Keane, J.A. Belperio, Y.Y. Xue, M.D. Burdick and R.M. Strieter (2004) Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 172 2853-2860.
134. M. Oshima, J.E. Dinchuk, S.L. Kargman, H. Oshima, B. Hancock, E. Kwong, J.M. Trzaskos, J.F. Evans and M.M. Taketo (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 803-809.
135. M.M. Taketo (1998) COX-2 and colon cancer. Inflamm Res 47(Suppl 2), S112-S116.
136. R. Langenbach, C. Loftin, C. Lee and H. Tiano (1999) Cyclooxygenase knockout mice: models for elucidating isoform-specific functions. Biochem Pharmacol 58 1237-1246.
137. X. Zhang, S.G. Morham, R. Langenbach, R.B. Baggs and D.A. Young (2000) Lack of cyclooxygenase-2 inhibits growth of teratocarcinomas in mice. Exp Cell Res 254 232-240.
138. K.M. Leahy, A.T. Koki and J.L. Masferrer (2000) Role of cyclooxygenases in angiogenesis. Curr Med Chem 7 1163-1170.
139. J. Masferrer (2001) Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J 7(Suppl 3), S144-S150.
140. T. Cheng, W. Cao, R. Wen, R.H. Steinberg and M.M. LaVail (1998) Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci 39 581-591.
141. R. Pai, I.L. Szabo, B.A. Soreghan, S. Atay, H. Kawanaka and A.S. Tarnawski (2001) PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 286 923-928.
142. Y. Sakai, K. Fujita, H. Sakai and K. Mizuno (2001) Prostaglandin E2 regulates the expression of basic fibroblast growth factor messenger RNA in normal human fibroblasts. Kobe J Med Sci 47 35-45.
143. O. Dormond, M. Bezzi, A. Mariotti and C. Ruegg (2002) Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J Biol Chem 277 45838-45846.
144. S. Sakurai, S. Alam, G. Pagan-Mercado, F. Hickman, J.Y. Tsai, P. Zelenka and S. Sato (2002) Retinal capillary pericyte proliferation and c-Fos mRNA induction by prostaglandin D2 through the cAMP response element. Invest Ophthalmol Vis Sci 43 2774-2781.
145. C. Hidai, T. Zupancic, K. Penta, A. Mikhail, M. Kawana, E.E. Quertermous, Y. Aoka, M. Fukagawa, Y. Matsui, D. Platika, R. Auerbach, B.L. Hogan, R. Snodgrass and T. Quertermous (1998) Cloning and characterization of developmental endothelial locus-1: an embryonic endothelial cell protein that binds the alphavbeta3 integrin receptor. Genes Dev 12 21-33.
146. H.K. Ho, J.J. Jang, S. Kaji, G. Spektor, A. Fong, P. Yang, B.S. Hu, R. Schatzman, T. Quertermous and J.P. Cooke (2004) Developmental endothelial locus-1 (Del-1), a novel angiogenic protein: its role in ischemia. Circulation 109 1314-1319.
147. K. Penta, J.A. Varner, L. Liaw, C. Hidai, R. Schatzman and T. Quertermous (1999) Del1 induces integrin signaling and angiogenesis by ligation of alphaVbeta3. J Biol Chem 274 11101-11109.
148. Y. Aoka, F.L. Johnson, K. Penta, K. Hirata Ki, C. Hidai, R. Schatzman, J.A. Varner and T. Quertermous (2002) The embryonic angiogenic factor Del1 accelerates tumor growth by enhancing vascular formation. Microvasc Res 64 148-161.
149. J. LeCouter, J. Kowalski, J. Foster, P. Hass, Z. Zhang, L. Dillard-Telm, G. Frantz, L. Rangell, L. DeGuzman, G.A. Keller, F. Peale, A. Gurney, K.J. Hillan and N. Ferrara (2001) Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412 877-884.
150. N. Ferrara, J. LeCouter and R. Lin (2002) Endocrine gland vascular endothelial growth factor (EG-VEGF) and the hypothesis of tissue-specific regulation of angiogenesis. Endocr Res 28 763-764.
151. T. Kisliouk, N. Levy, A. Hurwitz and R. Meidan (2003) Presence and regulation of endocrine gland vascular endothelial growth factor/prokineticin-1 and its receptors in ovarian cells. J Clin Endocrinol Metab 88 3700-3707.
152. L. Zhang, N. Yang, J.R. Conejo-Garcia, D. Katsaros, A. Mohamed-Hadley, S. Fracchioli, K. Schlienger, A. Toll, B. Levine, S.C. Rubin and G. Coukos (2003) Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clin Cancer Res 9 264-272.
153. J.Y. Chung, Y. Song, Y. Wang, R.R. Magness and J. Zheng (2004) Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J Clin Endocrinol Metab 89 2484-2490.
154. M. Samson, F.V. Peale Jr., G. Frantz, N. Rioux-Leclercq, E. Rajpert-De Meyts and N. Ferrara (2004) Human endocrine gland-derived vascular endothelial growth factor: expression early in development and in Leydig cell tumors suggests roles in normal and pathological testis angiogenesis. J Clin Endocrinol Metab 89 4078-4088.
155. Y. Masuda, Y. Takatsu, Y. Terao, S. Kumano, Y. Ishibashi, M. Suenaga, M. Abe, S. Fukusumi, T. Watanabe, Y. Shintani, T. Yamada, S. Hinuma, N. Inatomi, T. Ohtaki, H. Onda and M. Fujino (2002) Isolation and identification of EG-VEGF/prokineticins as cognate ligands for two orphan G-protein-coupled receptors. Biochem Biophys Res Commun 293 396-402.
156. J. LeCouter and N. Ferrara (2003) EG-VEGF and Bv8: a novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and function. Trends Cardiovasc Med 13 276-282.
157. N. Ferrara, J. LeCouter, R. Lin and F. Peale (2004) EG-VEGF and Bv8: a novel family of tissue-restricted angiogenic factors. Biochim Biophys Acta 1654 69-78.
158. D.C. Lin, C.M. Bullock, F.J. Ehlert, J.L. Chen, H. Tian and Q.Y. Zhou (2002) Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor. J Biol Chem 277 19276-19280.
159. M. Yoshida and M.A. Gimbrone Jr. (1997) Novel roles for E-selectin in endothelial-leukocyte adhesion. Ann NY Acad Sci 811 493-497.
160. M. Nguyen, N.A. Strubel and J. Bischoff (1993) A role for sialyl Lewis-X/A glycoconjugates in capillary morphogenesis. Nature 365 267-269.
161. M. Aoki, M. Kanamori, K. Yudoh, K. Ohmori, T. Yasuda and T. Kimura (2001) Effects of vascular endothelial growth factor and E-selectin on angiogenesis in the murine metastatic RCT sarcoma. Tumor Biol 22 239-246.
162. J. Bischoff, C. Brasel, B. Kraling and K. Vranovska (1997) E-selectin is upregulated in proliferating endothelial cells in vitro. Microcirculation 4 279-287.
163. B.M. Wittig, H. Kaulen, R. Thees, C. Schmitt, P. Knolle, J. Stock, K.H. Meyer zum Buschenfelde and W. Dippold (1996) Elevated serum E-selectin in patients with liver metastases of colorectal cancer. Eur J Cancer 32A 1215-1218.
164. M. Hebbar, F. Revillion, M.M. Louchez, M.O. Vilain, C. Fournier, J. Bonneterre and J.P. Peyrat (1998) The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer. Clin Cancer Res 4 373-380.
165. G.J. Byrne, A. Ghellal, J. Iddon, A.D. Blann, V. Venizelos, S. Kumar, A. Howell and N.J. Bundred (2000) Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 92 1329-1336.
166. S.M. Sheen-Chen, H.L. Eng, C.C. Huang and W.J. Chen (2004) Serum levels of soluble E-selectin in women with breast cancer. Br J Surg 91 1578-1581.
167. A.E. Koch, M.M. Halloran, C.J. Haskell, M.R. Shah and P.J. Polverini (1995) Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376 517-519.
168. D.S. Milstone, D. Fukumura, R.C. Padgett, P.E. O'Donnell, V.M. Davis, O.J. Benavidez, W.L. Monsky, R.J. Melder, R.K. Jain and M.A. Gimbrone Jr. (1998) Mice lacking E-selectin show normal numbers of rolling leukocytes but reduced leukocyte stable arrest on cytokine-activated microvascular endothelium. Microcirculation 5 153-171.
169. Y. Yu, K.S. Moulton, M.K. Khan, S. Vineberg, E. Boye, V.M. Davis, P.E. O'Donnell, J. Bischoff and D.S. Milstone (2004) E-selectin is required for the antiangiogenic activity of endostatin. Proc Natl Acad Sci USA 101 8005-8010.
170. N. Cheng, D.M. Brantley and J. Chen (2002) The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 13 75-85.
171. D. Brantley-Sieders, M. Parker and J. Chen (2004) Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 10 3431-3442.
172. R.H. Adams, G.A. Wilkinson, C. Weiss, F. Diella, N.W. Gale, U. Deutsch, W. Risau and R. Klein (1999) Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 13 295-306.
173. R.H. Adams and R. Klein (2000) Eph receptors and ephrin ligands: essential mediators of vascular development. Trends Cardiovasc Med 10 183-188.
174. R.H. Adams (2002) Vascular patterning by Eph receptor tyrosine kinases and ephrins. Semin Cell Dev Biol 13 55-60.
175. S.S. Gerety and D.J. Anderson (2002) Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. Development 129 1397-1410.
176. H. Surawska, P. Ma and R. Salgia (2004) The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15 419-433.
177. N. Cheng, D.M. Brantley, H. Liu, Q. Lin, M. Enriquez, N. Gale, G. Yancopoulos, D.P. Cerretti, T.O. Daniel and J. Chen (2002) Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1 2-11.
178. T. Fuller, T. Korff, A. Kilian, G. Dandekar and H.G. Augustin (2003) Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells. J Cell Sci 116 2461-2470.
179. G. Martiny-Baron, T. Korff, F. Schaffner, N. Esser, S. Eggstein, D. Marme and H.G. Augustin (2004) Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 6 248-257.
180. F. Esch, S. Shimasaki, M. Mercado, K. Cooksey, N. Ling, S. Ying, N. Ueno and R. Guillemin (1987) Structural characterization of follistatin: a novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad. Mol Endocrinol 1
181. D. Robertson, R. Klein, F. De Vos, R. McLachlan, R. Wettenhall, M. Hearn, H. Burger and D. de Kretser (1987) The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin. Biochem Biophys Res Commun 149 744-749.
182. D. Phillips and D. de Kretser (1998) Follistatin: a multifunctional regulatory protein. Front Neuroendocrinol 19 287-322.
183. R.O. Hynes (2002) A reevaluation of integrins as regulators of angiogenesis. Nat Med 8 918-921.
184. R.O. Hynes, J.C. Lively, J.H. McCarty, D. Taverna, S.E. Francis, K. Hodivala-Dilke and Q. Xiao (2002) The diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb Symp Quant Biol 67 143-153.
185. M. Friedlander, P.C. Brooks, R.W. Shaffer, C.M. Kincaid, J.A. Varner and D.A. Cheresh (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270 1500-1502.
186. D.R. Senger, C.A. Perruzzi, M. Streit, V.E. Koteliansky, A.R. de Fougerolles and M. Detmar (2002) The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am J Pathol 160 195-204.
187. V. Ramakrishnan, V. Bhaskar, D.A. Law, M.H. Wong, R.B. DuBridge, D. Breinberg, C. O'Hara, D.B. Powers, G. Liu, J. Grove, P. Hevezi, K.M. Cass, S. Watson, F. Evangelista, R.A. Powers, B. Finck, M. Wills, I. Caras, Y. Fang, D. McDonald, D. Johnson, R. Murray and U. Jeffry (2006) Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 5 273-286.
188. C.A. Partridge, P.G. Phillips, M.J. Niedbala and J.J. Jeffrey (1997) Localization and activation of type IV collagenase/gelatinase at endothelial focal contacts. Am J Physiol 272 L813-L822.
189. P. Carmeliet, M.G. Lampugnani, L. Moons, F. Breviario, V. Compernolle, F. Bono, G. Balconi, R. Spagnuolo, B. Oostuyse, M. Dewerchin, A. Zanetti, A. Angellilo, V. Mattot, D. Nuyens, E. Lutgens, F. Clotman, M.C. de Ruiter, A. Gittenberger-de Groot, R. Poelmann, F. Lupu, J.M. Herbert, D. Collen and E. Dejana (1999) Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98 147-157.
190. T.L. Bach, C. Barsigian, D.G. Chalupowicz, D. Busler, C.H. Yaen, D.S. Grant and J. Martinez (1998) VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp Cell Res 238 324-334.
191. S. Yang, J. Graham, J.W. Kahn, E.A. Schwartz and M.E. Gerritsen (1999) Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels. Am J Pathol 155 887-895.
192. G. Breier, F. Breviario, L. Caveda, R. Berthier, H. Schnurch, U. Gotsch, D. Vestweber, W. Risau and E. Dejana (1996) Molecular cloning and expression of murine vascular endothelial-cadherin in early stage development of cardiovascular system. Blood 87 630-641.
193. F. Liao, Y. Li, W. O'Connor, L. Zanetta, R. Bassi, A. Santiago, J. Overholser, A. Hooper, P. Mignatti, E. Dejana, D.J. Hicklin and P. Bohlen (2000) Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res 60 6805-6810.
194. M. Corada, F. Liao, M. Lindgren, M.G. Lampugnani, F. Breviario, R. Frank, W.A. Muller, D.J. Hicklin, P. Bohlen and E. Dejana (2001) Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. Blood 97 1679-1684.
195. M. Corada, L. Zanetta, F. Orsenigo, F. Breviario, M.G. Lampugnani, S. Bernasconi, F. Liao, D.J. Hicklin, P. Bohlen and E. Dejana (2002) A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100 905-911.
196. F. Liao, J.F. Doody, J. Overholser, B. Finnerty, R. Bassi, Y. Wu, E. Dejana, P. Kussie, P. Bohlen and D.J. Hicklin (2002) Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Cancer Res 62 2567-2575.
197. D.E. Jackson (2003) The unfolding tale of PECAM-1. FEBS Lett 540 7-14.
198. H.M. DeLisser, M. Christofidou-Solomidou, R.M. Strieter, M.D. Burdick, C.S. Robinson, R.S. Wexler, J.S. Kerr, C. Garlanda, J.R. Merwin, J.A. Madri and S.M. Albelda (1997) Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151 671-677.
199. G. Cao, C.D. O'Brien, Z. Zhou, S.M. Sanders, J.N. Greenbaum, A. Makrigiannakis and H.M. DeLisser (2002) Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. Am J Physiol Cell Physiol 282 C1181-C1190.
200. G.S. Duncan, D.P. Andrew, H. Takimoto, S.A. Kaufman, H. Yoshida, J. Spellberg, J. Luis de la Pompa, A. Elia, A. Wakeham, B. Karan-Tamir, W.A. Muller, G. Senaldi, M.M. Zukowski and T.W. Mak (1999) Genetic evidence for functional redundancy of platelet/endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1-dependent and PECAM-1-independent functions. J Immunol 162 3022-3030.
201. I. Hamaguchi, X.L. Huang, N. Takakura, J. Tada, Y. Yamaguchi, H. Kodama and T. Suda (1999) In vitro hematopoietic and endothelial cell development from cells expressing TEK receptor in murine aorta-gonad-mesonephros region. Blood 93 1549-1556.
202. S. Mahooti, D. Graesser, S. Patil, P. Newman, G. Duncan, T. Mak and J.A. Madri (2000) PECAM-1 (CD31) expression modulates bleeding time in vivo. Am J Pathol 157 75-81.
203. R.D. Thompson, K.E. Noble, K.Y. Larbi, A. Dewar, G.S. Duncan, T.W. Mak and S. Nourshargh (2001) Platelet-endothelial cell adhesion molecule-1 (PECAM-1)-deficient mice demonstrate a transient and cytokine-specific role for PECAM-1 in leukocyte migration through the perivascular basement membrane. Blood 97 1854-1860.
204. D. Graesser, A. Solowiej, M. Bruckner, E. Osterweil, A. Juedes, S. Davis, N.H. Ruddle, B. Engelhardt and J.A. Madri (2002) Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J Clin Invest 109 383-392.
205. V. Paracchini, P. Pedotti and E. Taioli (2005) Genetics of leptin and obesity: a HuGE review. Am J Epidemiol 162 101-114.
206. M.R. Sierra-Honigmann, A.K. Nath, C. Murakami, G. Garcia-Cardena, A. Papapetropoulos, W.C. Sessa, L.A. Madge, J.S. Schechner, M.B. Schwabb, P.J. Polverini and J.R. Flores-Riveros (1998) Biological action of leptin as an angiogenic factor. Science 281 1683-1686.
207. A. Bouloumie, H.C. Drexler, M. Lafontan and R. Busse (1998) Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 83 1059-1066.
208. B.D. Ring, S. Scully, C.R. Davis, M.B. Baker, M.J. Cullen, M.A. Pelleymounter and D.M. Danilenko (2000) Systemically and topically administered leptin both accelerate wound healing in diabetic ob/ob mice. Endocrinology 141 446-449.
209. J.A. Cioffi, J. Van Blerkom, M. Antczak, A. Shafer, S. Wittmer and H.R. Snodgrass (1997) The expression of leptin and its receptors in pre-ovulatory human follicles. Mol Hum Reprod 3 467-472.
210. M.G. Riad-Gabriel, S.D. Jinagouda, A. Sharma, R. Boyadjian and M.F. Saad (1998) Changes in plasma leptin during the menstrual cycle. Eur J Endocrinol 139 528-531.
211. A. Kurtz, A.M. Schulte and A. Wellstein (1995) Pleiotrophin and midkine in normal development and tumor biology. Crit Rev Oncog 6 151-177.
212. N. Zhang and T.F. Deuel (1999) Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. Curr Opin Hematol 6 44-50.
213. R.I. Garver Jr., D.M. Radford, H. Donis-Keller, M.R. Wick and P.G. Milner (1994) Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 74 1584-1590.
214. T. O'Brien, D. Cranston, S. Fuggle, R. Bicknell and A.L. Harris (1996) The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 56 2515-2518.
215. R. Choudhuri, H.T. Zhang, S. Donnini, M. Ziche and R. Bicknell (1997) An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 57 1814-1819.
216. J.R. Westphal, R. Van't Hullenaar, R. Peek, R.W. Willems, K. Crickard, U. Crickard, J. Askaa, I. Clemmensen, D.J. Ruiter and R.M. De Waal (2000) Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer 86 768-776.
217. G.E. Stoica, A. Kuo, C. Powers, E.T. Bowden, E.B. Sale, A.T. Riegel and A. Wellstein (2002) Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 277 35990-35998.
218. E. Papadimitriou, A. Polykratis, M. Hatziapostolou, A. Parthymou, C. Polytarchou and C. Mikelis (2004) Heparin affin regulatory peptide: a new target for tumour therapy? Curr Cancer Drug Targets 4 471-482.
219. N. Maeda, T. Nishiwaki, T. Shintani, H. Hamanaka and M. Noda (1996) 6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/ heparin-binding growth-associated molecule (HB-GAM). J Biol Chem 271 21446-21452.
220. N. Maeda and M. Noda (1998) Involvement of receptor-like protein tyrosine phosphatase zeta/RPTPbeta and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migration. J Cell Biol 142 203-216.
221. B.M. Weinstein and N.D. Lawson (2002) Arteries, veins, Notch, and VEGF. Cold Spring Harb Symp Quant Biol 67 155-162.
222. T. Iso, Y. Hamamori and L. Kedes (2003) Notch signaling in vascular development. Arterioscler Thromb Vasc Biol 23 543-553.
223. J.A. Alva and M.L. Iruela-Arispe (2004) Notch signaling in vascular morphogenesis. Curr Opin Hematol 11 278-283.
224. M. Hrabe de Angelis, J. McIntyre 2nd and A. Gossler (1997) Maintenance of somite borders in mice requires the Delta homologue DII1. Nature 386 717-721.
225. Y. Xue, X. Gao, C.E. Lindsell, C.R. Norton, B. Chang, C. Hicks, M. Gendron-Maguire, E.B. Rand, G. Weinmaster and T. Gridley (1999) Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum Mol Genet 8 723-730.
226. L.T. Krebs, Y. Xue, C.R. Norton, J.R. Shutter, M. Maguire, J.P. Sundberg, D. Gallahan, V. Closson, J. Kitajewski, R. Callahan, G.H. Smith, K.L. Stark and T. Gridley (2000) Notch signaling is essential for vascular morphogenesis in mice. Genes Dev 14 1343-1352.
227. B. McCright, X. Gao, L. Shen, J. Lozier, Y. Lan, M. Maguire, D. Herzlinger, G. Weinmaster, R. Jiang and T. Gridley (2001) Defects in development of the kidney, heart and eye vasculature in mice homozygous for a hypomorphic Notch2 mutation. Development 128 491-502.
228. H. Uyttendaele, J. Ho, J. Rossant and J. Kitajewski (2001) Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc Natl Acad Sci USA 98 5643-5648.
229. N.W. Gale, M.G. Dominguez, I. Noguera, L. Pan, V. Hughes, D.M. Valenzuela, A.J. Murphy, N.C. Adams, H.C. Lin, J. Holash, G. Thurston and G.D. Yancopoulos (2004) Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci USA 101 15949-15954.
230. A. Joutel, C. Corpechot, A. Ducros, K. Vahedi, H. Chabriat, P. Mouton, S. Alamowitch, V. Domenga, M. Cecillion, E. Marechal, J. Maciazek, C. Vayssiere, C. Cruaud, E.A. Cabanis, M.M. Ruchoux, J. Weissenbach, J.F. Bach, M.G. Bousser and E. Tournier-Lasserve (1996) Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383 707-710.
231. A. Joutel, C. Corpechot, A. Ducros, K. Vahedi, H. Chabriat, P. Mouton, S. Alamowitch, V. Domenga, M. Cecillion, E. Marechal, J. Maciazek, C. Vayssiere, C. Cruaud, E.A. Cabanis, M.M. Ruchoux, J. Weissenbach, J.F. Bach, M.G. Bousser and E. Tournier-Lasserve (1997) Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia. Ann NY Acad Sci 826 213-217.
232. A. Joutel, K. Vahedi, C. Corpechot, A. Troesch, H. Chabriat, C. Vayssiere, C. Cruaud, J. Maciazek, J. Weissenbach, M.G. Bousser, J.F. Bach and E. Tournier-Lasserve (1997) Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 350 1511-1515.
233. S. Salloway and J. Hong (1998) CADASIL syndrome: a genetic form of vascular dementia. J Geriatr Psychiatry Neurol 11 71-77.
234. Z.R. Yuan, T. Kohsaka and N. Kobayashi (1997) Linkage analysis and identification of deletion in Alagille syndrome gene. Acta Paediatr Jpn 39 647-652.
235. I.D. Krantz, R.P. Colliton, A. Genin, E.B. Rand, L. Li, D.A. Piccoli and N.B. Spinner (1998) Spectrum and frequency of jagged1 (JAG1) mutations in Alagille syndrome patients and their families. Am J Hum Genet 62 1361-1369.
236. Z.R. Yuan, T. Kohsaka, T. Ikegaya, T. Suzuki, S. Okano, J. Abe, N. Kobayashi and M. Yamada (1998) Mutational analysis of the Jagged 1 gene in Alagille syndrome families. Hum Mol Genet 7 1363-1369.
237. I.D. Krantz, D.A. Piccoli and N.B. Spinner (1999) Clinical and molecular genetics of Alagille syndrome. Curr Opin Pediatr 11 558-564.
238. A. Fischer, N. Schumacher, M. Maier, M. Sendtner and M. Gessler (2004) The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genes Dev 18 901-911.
239. F. MacKenzie, P. Duriez, F. Wong, M. Noseda and A. Karsan (2004) Notch4 inhibits endothelial apoptosis via RBP-Jkappa-dependent and -independent pathways. J Biol Chem 279 11657-11663.
240. W. Wang, C.Z. Prince, Y. Mou and M.J. Pollman (2002) Notch3 signaling in vascular smooth muscle cells induces c-FLIP expression via ERK/MAPK activation. Resistance to Fas ligand-induced apoptosis. J Biol Chem 277 21723-21729.
241. N. Villa, L. Walker, C.E. Lindsell, J. Gasson, M.L. Iruela-Arispe and G. Weinmaster (2001) Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech Dev 108 161-164.
242. Z.J. Liu, T. Shirakawa, Y. Li, A. Soma, M. Oka, G.P. Dotto, R.M. Fairman, O.C. Velazquez and M. Herlyn (2003) Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 23 14-25.
243. C. Mailhos, U. Modlich, J. Lewis, A. Harris, R. Bicknell and D. Ish-Horowicz (2001) Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 69 135-144.
244. M. Hellstrom, L.K. Phng, J.J. Hofmann, E. Wallgard, L. Coultas, P. Lindblom, J. Alva, A.K. Nilsson, L. Karlsson, N. Gaiano, K. Yoon, J. Rossant, M.L. Iruela-Arispe, M. Kalen, H. Gerhardt and C. Betsholtz (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature
245. A.F. Siekmann and N.D. Lawson (2007) Notch signalling limits angiogenic cell behavior in developing zebrafish arteries. Nature
246. I. Noguera-Troise, C. Daly, N.J. Papadopoulos, S. Coetzee, P. Boland, N.W. Gale, H.C. Lin, G.D. Yancopoulos and G. Thurston (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444 1032-1037.
247. J. Ridgway, G. Zhang, Y. Wu, S. Stawicki, W.C. Liang, Y. Chanthery, J. Kowalski, R.J. Watts, C. Callahan, I. Kasman, M. Singh, M. Chien, C. Tan, J.A. Hongo, F. de Sauvage, G. Plowman and M. Yan (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444 1083-1087.
248. M. Thibonnier, D. Conarty, J. Preston, C. Pleshicher, R. Dweik and S. Erzurium (1999) Human vascular endothelial cells express oxytocin receptors. Endocrinology 140 1301-1309.
249. P. Cassoni, T. Marrocco, B. Bussolati, E. Allia, L. Munaron, A. Sapino and G. Bussolati (2006) Oxytocin induces proliferation and migration in immortalized human dermal microvascular endothelial cells and human breast tumor-derived endothelial cells. Mol Cancer Res 4 351-359.
250. G.J. Peters, M. De Bruin, M. Fukushima, B. Van Triest, K. Hoekman, H.M. Pinedo and S.P. Ackland (2000) Thymidine phosphorylase in angiogenesis and drug resistance. Homology with platelet-derived endothelial cell growth factor. Adv Exp Med Biol 486 291-294.
251. S. Akiyama, T. Furukawa, T. Sumizawa, Y. Takebayashi, Y. Nakajima, S. Shimaoka and M. Haraguchi (2004) The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci 95 851-857.
252. A. Carbacho, G.M. de La Escalera and C. Clapp (2002) Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 173 219-238.
253. C. Clapp, J.A. Martial, R.C. Guzman, F. Rentier-Delure and R.I. Weiner (1993) The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133 1292-1299.
254. N. Ferrara, C. Clapp and R. Weiner (1991) The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 129 896-900.
255. C. Gonzalez, A.M. Corbacho, J.P. Eiserich, C. Garcia, F. Lopez-Barrera, V. Morales-Tlalpan, A. Barajas-Espinosa, M. Diaz-Munoz, R. Rubio, S.H. Lin, G. Martinez de la Escalera and C. Clapp (2004) 16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation. Endocrinology 145 5714-5722.
256. A. Ochoa, P. Montes de Oca, J.C. Rivera, Z. Duenas, G. Nava, G.M. de La Escalera and C. Clapp (2001) Expression of prolactin gene and secretion of prolactin by rat retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 42 1639-1645.
257. N.D. Horseman, W. Zhao, E. Montecino-Rodriguez, M. Tanaka, K. Nakashima, S.J. Engle, F. Smith, E. Markoff and K. Dorshkind (1997) Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. Embo J 16 6926-6935.
258. A.J. Vomachka, S.L. Pratt, J.A. Lockefeer and N.D. Horseman (2000) Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 19 1077-1084.
259. D.I. Linzer, S.J. Lee, L. Ogren, F. Talamantes and D. Nathans (1985) Identification of proliferin mRNA and protein in mouse placenta. Proc Natl Acad Sci USA 82 4356-4359.
260. S.J. Lee, F. Talamantes, E. Wilder, D.I. Linzer and D. Nathans (1988) Trophoblastic giant cells of the mouse placenta as the site of proliferin synthesis. Endocrinology 122 1761-1768.
261. O. Volpert, D. Jackson, N. Bouch and D.I.H. Linzer (1996) The insulin-like growth factor II/Mannose 6-phosphate receptor is required for proliferin-induced angiogenesis. Endocrinology 137 3871-3876.
262. M.A. Lafleur, M.M. Handsley and D.R. Edwards (2003) Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med 5 1-39.
263. R.A. Black and J.M. White (1998) ADAMs: focus on the protease domain. Curr Opin Cell Biol 10 654-659.
264. J. Schlondorff and C.P. Blobel (1999) Metalloprotease-disintegrins: modular proteins capable of promoting cell–cell interactions and triggering signals by protein-ectodomain shedding. J Cell Sci 112(Pt 21), 3603-3617.
265. J. White (2003) ADAMs: modulators of cell–cell and cell–matrix interactions. Curr Opin Cell Biol 15 598-606.
266. C. Brou, F. Logeat, N. Gupta, C. Bessia, O. LeBail, J.R. Doedens, A. Cumano, P. Roux, R.A. Black and A. Israel (2000) A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 5 207-216.
267. D. Hartmann, B. de Strooper, L. Serneels, K. Craessaerts, A. Herreman, W. Annaert, L. Umans, T. Lubke, A. Lena Illert, K. von Figura and P. Saftig (2002) The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 11 2615-2624.
268. C.E. Bland, P. Kimberly and M.D. Rand (2003) Notch-induced proteolysis and nuclear localization of the Delta ligand. J Biol Chem 278 13607-13610.
269. M.J. LaVoie and D.J. Selkoe (2003) The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem 278 34427-34437.
270. E. Six, D. Ndiaye, Y. Laabi, C. Brou, N. Gupta-Rossi, A. Israel and F. Logeat (2003) The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and gamma-secretase. Proc Natl Acad Sci USA 100 7638-7643.
271. T. Bogenrieder and M. Herlyn (2002) Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma. Crit Rev Oncol Hematol 44 1-15.
272. T. Asahara, H. Masuda, T. Takahashi, C. Kalka, C. Pastore, M. Silver, M. Kearne, M. Magner and J.M. Isner (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85 221-228.
273. P. Carmeliet and A. Luttun (2001) The emerging role of the bone marrow-derived stem cells in (therapeutic) angiogenesis. Thromb Haemost 86 289-297.
274. C. Urbich and S. Dimmeler (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95 343-353.
275. T. Asahara and J.M. Isner (2002) Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res 11 171-178.
276. A. Luttun, G. Carmeliet and P. Carmeliet (2002) Vascular progenitors: from biology to treatment. Trends Cardiovasc Med 12 88-96.
277. T. Murayama and T. Asahara (2002) Bone marrow-derived endothelial progenitor cells for vascular regeneration. Curr Opin Mol Ther 4 395-402.
278. J.J. Zwaginga and P. Doevendans (2003) Stem cell-derived angiogenic/vasculogenic cells: possible therapies for tissue repair and tissue engineering. Clin Exp Pharmacol Physiol 30 900-908.
279. T. Asahara, T. Takahashi, H. Masuda, C. Kalka, D. Chen, H. Iwaguro, Y. Inai, M. Silver and J.M. Isner (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J 18 3964-3972.
280. H. Kamihata, H. Matsubara, T. Nishiue, S. Fujiyama, Y. Tsutsumi, R. Ozono, H. Masaki, Y. Mori, O. Iba, E. Tateishi, A. Kosaki, S. Shintani, T. Murohara, T. Imaizumi and T. Iwasaka (2001) Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 104 1046-1052.
281. S. Shintani, T. Murohara, H. Ikeda, T. Ueno, K. Sasaki, J. Duan and T. Imaizumi (2001) Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation 103 897-903.
282. J.M. Edelberg, L. Tang, K. Hattori, D. Lyden and S. Rafii (2002) Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ Res 90 E89-E93.
283. I. Rajantie, M. Ilmonen, A. Alminaite, U. Ozerdem, K. Alitalo and P. Salven (2004) Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104 2084-2086.
284. T. Ziegelhoeffer, B. Fernandez, S. Kostin, M. Heil, R. Voswinckel, A. Helisch and W. Schaper (2004) Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 94 230-238.
285. S. Porter, I.M. Clark, L. Kevorkian and D.R. Edwards (2004) The ADAMTS metalloproteinases. Biochem J
286. F. Vazquez, G. Hastings, M.A. Ortega, T.F. Lane, S. Oikemus, M. Lombardo and M.L. Iruela-Arispe (1999) METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 274 23349-23357.
287. K. Kuno, K. Bannai, M. Hakozaki, K. Matsushima and K. Hirose (2004) The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. Biochem Biophys Res Commun 319 1327-1333.
288. E.E. Voest, B.M. Kenyon, M.S. O'Reilly, G. Truitt, R.J. D'Amato and J. Folkman (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87 581-586.
289. S. Majewski, M. Marczak, A. Szmurlo, S. Jablonska and W. Bollag (1996) Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J Invest Dermatol 106 1114-1118.
290. S. Hiscox and W.G. Jiang (1997) Interleukin-12, an emerging anti-tumour cytokine. In Vivo 11 125-132.
291. M. Strasly, F. Cavallo, M. Geuna, S. Mitola, M.P. Colombo, G. Forni and F. Bussolino (2001) IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol 166 3890-3899.
292. J. Chao, D.M. Tillman, M.Y. Wang, H.S. Margolius and L. Chao (1986) Identification of a new tissue-kallikrein-binding protein. Biochem J 239 325-331.
293. M.Y. Wang, J. Day, L. Chao and J. Chao (1989) Human kallistatin, a new tissue kallikrein-binding protein: purification and characterization. Adv Exp Med Biol 247B 1-8.
294. J. Chao, R.Q. Miao, V. Chen, L.M. Chen and L. Chao (2001) Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol Chem 382 15-21.
295. E. Rian, R. Jemtland, O.K. Olstad, M.J. Endresen, W.A. Grasser, M.A. Thiede, T. Henriksen, E. Bucht and K.M. Gautvik (1994) Parathyroid hormone-related protein is produced by cultured endothelial cells: a possible role in angiogenesis. Biochem Biophys Res Commun 198 740-747.
296. L.J. Deftos (2000) Prostate carcinoma: production of bioactive factors. Cancer 88 3002-3008.
297. K. Akino, A. Ohtsuru, K. Kanda, A. Yasuda, T. Yamamoto, Y. Akino, S. Naito, M. Kurokawa, N. Iwahori and S. Yamashita (2000) Parathyroid hormone-related peptide is a potent tumor angiogenic factor. Endocrinology 141 4313-4316.
298. M.M. Bakre, Y. Zhu, H. Yin, D.W. Burton, R. Terkeltaub, L.J. Deftos and J.A. Varner (2002) Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. Nat Med 8 995-1003.
299. J. Tombran-Tink, G.G. Chader and L.V. Johnson (1991) PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 53 411-414.
300. F.R. Steele, G.J. Chader, L.V. Johnson and J. Tombran-Tink (1993) Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci USA 90 1526-1530.
301. Y. Sugita, S.P. Becerra, G.J. Chader and J.P. Schwartz (1997) Pigment epithelium-derived factor (PEDF) has direct effects on the metabolism and proliferation of microglia and indirect effects on astrocytes. J Neurosci Res 49 710-718.
302. W. Cao, J. Tombran-Tink, W. Chen, D. Mrazek, R. Elias and J.F. McGinnis (1999) Pigment epithelium-derived factor protects cultured retinal neurons against hydrogen peroxide-induced cell death. J Neurosci Res 57 789-800.
303. D.W. Dawson, O.V. Volpert, P. Gillis, S.E. Crawford, H. Xu, W. Benedict and N.P. Bouck (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285 245-248.
304. N. Bouck (2002) PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 8 330-334.
305. V. Stellmach, S.E. Crawford, W. Zhou and N. Bouck (2001) Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 98 2593-2597.
306. J.A. Doll, V.M. Stellmach, N.P. Bouck, A.R. Bergh, C. Lee, L.P. Abramson, M.L. Cornwell, M.R. Pins, J. Borensztajn and S.E. Crawford (2003) Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 9 774-780.
307. R. Abe, T. Shimizu, S. Yamagishi, A. Shibaki, S. Amano, Y. Inagaki, H. Watanabe, H. Sugawara, H. Nakamura, M. Takeuchi, T. Imaizumi and H. Shimizu (2004) Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol 164 1225-1232.
308. K.K. Wary, G.D. Thakker, J.O. Humtsoe and J. Yang (2003) Analysis of VEGF-responsive genes involved in the activation of endothelial cells. Mol Cancer 2 25.
309. M.E. Gerritsen, R. Soriano, S. Yang, G. Ingle, C. Zlot, K. Toy, J. Winer, A. Draksharapu, F. Peale, T.D. Wu and P.M. Williams (2002) In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. Physiol Genomics 10 13-20.
310. A. Lal, H. Peters, B. St Croix, Z.A. Haroon, M.W. Dewhirst, R.L. Strausberg, J.H. Kaanders, A.J. van der Kogel and G.J. Riggins (2001) Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93 1337-1343.
311. C.R. McCudden, K.A. James, C. Hasilo and G.F. Wagner (2002) Characterization of mammalian stanniocalcin receptors. Mitochondrial targeting of ligand and receptor for regulation of cellular metabolism. J Biol Chem, 277 45249-45258.
312. K. Wakasugi and P. Schimmel (1999) Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 284 147-151.
313. K. Wakasugi and P. Schimmel (1999) Highly differentiated motifs responsible for two cytokine activities of a split human tRNA synthetase. J Biol Chem 274 23155-23159.
314. K. Wakasugi, B.M. Slike, J. Hood, A. Otani, K.L. Ewalt, M. Friedlander, D.A. Cheresh and P. Schimmel (2002) A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. Proc Natl Acad Sci USA 99 173-177.
315. A. Otani, B.M. Slike, M.I. Dorrell, J. Hood, K. Kinder, K.L. Ewalt, D. Cheresh, P. Schimmel and M. Friedlander (2002) A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. Proc Natl Acad Sci USA 99 178-183.
316. J. Liu, E. Shue, K.L. Ewalt and P. Schimmel (2004) A new gamma-interferon-inducible promoter and splice variants of an anti-angiogenic human tRNA synthetase. Nucleic Acids Res 32 719-727.
317. E. Tzima, J.S. Reader, M. Irani-Tehrani, K.L. Ewalt, M.A. Schwartz and P. Schimmel (2005) VE-cadherin links tRNA synthetase cytokine to anti-angiogenic function. J Biol Chem 280 2405-2408.
318. Y. Zhai, J. Ni, G.W. Jiang, J. Lu, L. Xing, C. Lincoln, K.C. Carter, F. Janat, D. Kozak, S. Xu, L. Rojas, B.B. Aggarwal, S. Ruben, L.Y. Li, R. Gentz and G.L. Yu (1999) VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. Faseb J 13 181-189.
319. Y. Zhai, J. Yu, L. Iruela-Arispe, W.Q. Huang, Z. Wang, A.J. Hayes, J. Lu, G. Jiang, L. Rojas, M.E. Lippman, J. Ni, G.L. Yu and L.Y. Li (1999) Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 82 131-136.
320. F. Soncin, V. Mattot, F. Lionneton, N. Spruyt, F. Lepretre, A. Begue and D. Stehelin (2003) VE-statin, an endothelial repressor of smooth muscle cell migration. Embo J 22 5700-5711.
321. S.D. Morgenbesser, M.R. Dufault, T.B. St. Martin, E. Lim, M. Callahan, W. Weber, S.F. Winter, R.P. McLaren, B. Richards, B.P. Cook, C. Rouleau, Y. Jiang, R.G. Bagley, D. Barberio, V.R. Akmaev, M. Nacht, S.L. Madden, N.M. Greenberg and B.A. Teicher (2005) Characterization of EGFL7 expression and function in tumorigenesis and angiogenesis. Proc. AM. Assoc Cancer Res. 46 1103c.
322. R.S. Kerbel (2004) Vasohibin: the feedback on a new inhibitor of angiogenesis. J Clin Invest 114 884-886.
323. K. Watanabe, Y. Hasegawa, H. Yamashita, K. Shimizu, Y. Ding, M. Abe, H. Ohta, K. Imagawa, K. Hojo, H. Maki, H. Sonoda and Y. Sato (2004) Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 114 898-907.
324. M. Sund, L. Xie and R. Kalluri (2004) The contribution of vascular basement membranes and extracellular matrix to the mechanics of tumor angiogenesis. APMIS 112 450-462.
325. M.S. O'Reilly, T. Boehm, Y. Shing, N. Fukai, G. Vasios, W.S. Lane, E. Flynn, J.R. Birkhead, B.R. Olsen and J. Folkman (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 277-285.
326. P.C. Colorado, A. Torre, G. Kamphaus, Y. Maeshima, H. Hopfer, K. Takahashi, R. Volk, E.D. Zamborsky, S. Herman, P.K. Sarkar, M.B. Ericksen, M. Dhanabal, M. Simons, M. Post, D.W. Kufe, R.R. Weichselbaum, V.P. Sukhatme and R. Kalluri (2000) Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res 60 2520-2526.
327. G.D. Kamphaus, P.C. Colorado, D.J. Panka, H. Hopfer, R. Ramchandran, A. Torre, Y. Maeshima, J.W. Mier, V.P. Sukhatme and R. Kalluri (2000) Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 275 1209-1215.
328. G.A. He, J.X. Luo, T.Y. Zhang, F.Y. Wang and R.F. Li (2003) Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth. Biochem Biophys Res Commun 312 801-805.
329. D.J. Panka and J.W. Mier (2003) Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 278 37632-37636.
330. G.A. He, J.X. Luo, T.Y. Zhang, Z.S. Hu and F.Y. Wang (2004) The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells. Biochem Biophys Res Commun 318 354-360.
331. Y. Maeshima, A. Sudhakar, J.C. Lively, K. Ueki, S. Kharbanda, C.R. Kahn, N. Sonenberg, R.O. Hynes and R. Kalluri (2002) Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295 140-143.
332. A. Sudhakar, H. Sugimoto, C. Yang, J. Lively, M. Zeisberg and R. Kalluri (2003) Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci USA 100 4766-4771.
333. J. Lawler (2002) Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 6 1-12.
334. L.C. Armstrong and P. Bornstein (2003) Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 22 63-71.
335. B. Vailhe and J.J. Feige (2003) Thrombospondins as anti-angiogenic therapeutic agents. Curr Pharm Des 9 583-588.
336. M.L. Iruela-Arispe, A. Luque and N. Lee (2004) Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 36 1070-1078.
337. M.S. O'Reilly, L. Holmgren, Y. Shing, C. Chen, R.A. Rosenthal, Y. Cao, M. Moses, W.S. Lane, E.H. Sage and J. Folkman (1994) Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 59 471-482.
338. M.S. O'Reilly, L. Holmgren, Y. Shing, C. Chen, R.A. Rosenthal, M. Moses, W.S. Lane, Y. Cao, E.H. Sage and J. Folkman (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 315-328.
339. H. Larsson, P. Akerud, K. Nordling, E. Raub-Segall, L. Claesson-Welsh and I. Bjork (2001) A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. J Biol Chem 276 11996-12002.
340. J.C. Zhang, X. Qi, J. Juarez, M. Plunkett, F. Donate, R. Sakthivel, A.P. Mazar and K.R. McCrae (2002) Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides. Can J Physiol Pharmacol 80 85-90.
341. Y.L. Guo, S. Wang, D.J. Cao and R.W. Colman (2003) Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins. J Cell Biochem 89 622-632.
342. K. Kuba, K. Matsumoto, K. Date, H. Shimura, M. Tanaka and T. Nakamura (2000) HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60 6737-6743.
343. K. Kuba, K. Matsumoto, K. Ohnishi, T. Shiratsuchi, M. Tanaka and T. Nakamura (2000) Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells. Biochem Biophys Res Commun 279 846-852.
344. L. Xin, R. Xu, Q. Zhang, T.P. Li and R.B. Gan (2000) Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis. Biochem Biophys Res Commun 277 186-190.
345. D. Tomioka, N. Maehara, K. Kuba, K. Mizumoto, M. Tanaka, K. Matsumoto and T. Nakamura (2001) Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 61 7518-7524.
346. M. Nakabayashi, R. Morishita, H. Nakagami, K. Kuba, K. Matsumoto, T. Nakamura, Y. Tano and Y. Kaneda (2003) HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model. Diabetologia 46 115-123.
347. T. Kushibiki, K. Matsumoto, T. Nakamura and Y. Tabata (2004) Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin. Gene Ther 11 1205-1214.
348. J. Wen, K. Matsumoto, N. Taniura, D. Tomioka and T. Nakamura (2004) Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther 11 419-430.
349. P. Martin and J. Lewis (1989) Origins of the neurovascular bundle: interactions between developing nerves and blood vessels in embryonic chick skin. Int J Dev Biol 33 379-387.
350. H. Wang, Z. Chen and D.J. A (1998) Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin B2 and its receptor Eph-B4. Cell 93 741-753.
351. S.S. Gerety, H.U. Wang, Z.F. Chen and D.J. Anderson (1999) Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 4 403-414.
352. R. Fiore and A.W. Puschel (2003) The function of semaphorins during nervous system development. Front Biosci 8 s484-s499.
353. H. Seeliger, M. Guba, G.E. Koehl, A. Doenecke, M. Steinbauer, C.J. Bruns, C. Wagner, E. Frank, K.W. Jauch and E.K. Geissler (2004) Blockage of 2-deoxy-d-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 10 1843-1852.
354. O. Kessler, N. Shraga-Heled, T. Lange, N. Gutmann-Raviv, E. Sabo, L. Baruch, M. Machluf and G. Neufeld (2004) Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64 1008-1015.
355. W. Shoji, S. Isogai, M. Sato-Maeda, M. Obinata and J.Y. Kuwada (2003) Semaphorin3a1 regulates angioblast migration and vascular development in zebrafish embryos. Development 130 3227-3236.
356. D. Bates, G.I. Taylor, J. Minichiello, P. Farlie, A. Cichowitz, N. Watson, M. Klagsbrun, R. Mamluk and D.F. Newgreen (2003) Neurovascular congruence results from a shared patterning mechanism that utilizes Semaphorin3A and Neuropilin-1. Dev Biol 255 77-98.
357. G. Serini, D. Valdembri, S. Zanivan, G. Morterra, C. Burkhardt, F. Caccavari, L. Zammataro, L. Primo, L. Tamagnone, M. Logan, M. Tessier-Lavigne, M. Taniguchi, A.W. Puschel and F. Bussolino (2003) Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424 391-397.
358. O. Behar, J.A. Golden, H. Mashimo, F.J. Schoen and M.C. Fishman (1996) Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature 383 525-528.
359. C. Gu, Y. Yoshida, J. Livet, D.V. Reimert, F. Mann, J. Merte, C.E. Henderson, T.M. Jessell, A.L. Kolodkin and D.D. Ginty (2005) Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 307 265-268.
360. L. Redmond and A. Ghosh (2001) The role of Notch and Rho GTPase signaling in the control of dendritic development. Curr Opin Neurobiol 11 111-117.
361. B. Wang, Y. Xiao, B.B. Ding, N. Zhang, X. Yuan, L. Gui, K.X. Qian, S. Duan, Z. Chen, Y. Rao and J.G. Geng (2003) Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 4 19-29.
362. L. Huminiecki, M. Gorn, S. Suchting, R. Poulsom and R. Bicknell (2002) Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics 79 547-552.
363. Y.S. Mukouyama, D. Shin, S. Britsch, M. Taniguchi and D.J. Anderson (2002) Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell 109 693-705.
364. K. Jin, Y. Zhu, Y. Sun, X.O. Mao, L. Xie and D.A. Greenberg (2002) Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 99 11946-11950.
365. Y. Sun, K. Jin, L. Xie, J. Childs, X.O. Mao, A. Logvinova and D.A. Greenberg (2003) VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 111 1843-1851.
366. Y. Zhu, K. Jin, X.O. Mao and D.A. Greenberg (2003) Vascular endothelial growth factor promotes proliferation of cortical neuron precursors by regulating E2F expression. Faseb J 17 186-193.
367. D.M. Form and R. Auerbach (1983) PGE2 and angiogenesis. Proc Soc Exp Biol Med 172 214-218.
368. G. Serini and F. Bussolino (2004) Common cues in vascular and axon guidance. Physiology (Bethesda) 19 348-354.